Grow Pharmaceuticals was founded in 2016 with the specific intention of creating a pet-focused Broad Spectrum CBD soft chew treat. We are an affiliate of Animal Pharmaceuticals, www.anmpharm.com, a company with a history of creating innovative nutraceuticals and dermatological products for pets using popular nutritional ingredients that were originally designed for humans. From our inception, we have focused on providing a uniquely innovative product using cutting edge technology and the latest nutritional information to help pets stay healthy and happy.


For the past two years Grow Pharmaceuticals has focused on research: formulating our patent-pending CannaChews and developing the ideal system for production and delivery of Broad Spectrum CBD to pets. Our patent-pending, proprietary process involves isolating CBD, creating a matrix, then stabilizing the active ingredients resulting in a Broad Spectrum CBD soft chew; the preferred delivery option for active ingredients to pets. This ensures that our CannaChews are not only tested and safe, they are the best pet-focused Broad Spectrum CBD product available. Grow Pharmaceuticals was established with one goal in mind: to create a highly concentrated, Broad Spectrum CBD soft chew to improve the lives of pets. CBD can have a wide range of benefits; from easing anxiety to aiding in the treatment of cancer. As such, we believe that CannaChews are an important addition to the animal supplement market. So, we designed CannaChews to help pets live healthy, happy and long lives and to alleviate pet owners’ worries, concerns, and fears about their pets’ health.


Broad Spectrum CBD, required by law to be very low in tetrahydrocannabinol (THC), is the non-psychotropic version of cannabis. The 2014 Farm Bill (Agricultural Act of 2014) changed the legal status of hemp in the United States. Section 7606 conveyed to state Departments of Agriculture and institutions of higher learning the ability to grow, cultivate, process and market hemp. In August 2016 access was broadened with the issuance of a Statement of Principles by the USDA (also co-signed by DOJ, DEA and HHS/FDA) that federal agencies had a legal basis for the broad federal acceptance of hemp. The 2017 Omnibus Spending Bill included previous language preventing federal monies from being spent to “prohibit the transportation, processing, sale or use of industrial hemp that is grown or cultivated in accordance with” Section 7606 of the U.S. Farm Bill and clearly articulated state/international line transportation. Finally, on December 20, 2018, the President signed the 2018 Farm Bill, which includes a provision to legalize and monitor CBD under the Department of Agriculture.
We use CBD grown in the U.S., by state-licensed farmers. CBD grown in the U.S. supports farmers and is the main impetus behind the recent federal shift completely legalizing hemp growth in the USA. The passage of the 2018 Farm Bill, including provisions to fully legalize CBD growth in the U.S. follows the lead of many states which have long made it legal for U.S. farmers to grow hemp.